Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
01:49pm, Tuesday, 25'th Nov 2025
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product of
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
01:31pm, Tuesday, 25'th Nov 2025
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
Hims, Block, and NRG Just Launched Huge Stock Buybacks
05:34pm, Monday, 24'th Nov 2025
Several big-name stocks just announced notable increases to their share buyback programs. These actions signal confidence, indicating that these companies' management teams may see value in their stoc
Hims & Hers: The Growth Story Is Outside GLP-1s
08:23am, Monday, 24'th Nov 2025
Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
11:56am, Friday, 21'st Nov 2025
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 20'th Nov 2025
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option fo
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
05:27pm, Wednesday, 19'th Nov 2025
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie NYSE: ABBV, Eli Lilly NYSE: LLY, Pfizer NYSE: PFE, and Merck NYSE: MRK—and their lin
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?
12:46pm, Tuesday, 18'th Nov 2025
HIMS faces rising regulatory strain, margin pressure and competition despite strong revenue momentum.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
10:02am, Tuesday, 18'th Nov 2025
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
09:00am, Tuesday, 18'th Nov 2025
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
08:00am, Monday, 17'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has
Hims & Hers names ex-FDA official Deb Autor as first policy chief
06:06am, Monday, 17'th Nov 2025
Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy
06:00am, Monday, 17'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Office
Head-To-Head Review: Hims & Hers Health (NYSE:HIMS) vs. Clover Health Investments (NASDAQ:CLOV)
05:03am, Monday, 17'th Nov 2025
Clover Health Investments (NASDAQ: CLOV - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both medical companies, but which is the better investment? We will contrast the
AE Wealth Management LLC Purchases Shares of 5,859 Hims & Hers Health, Inc. $HIMS
03:29am, Monday, 17'th Nov 2025
AE Wealth Management LLC purchased a new stake in Hims and Hers Health, Inc. (NYSE: HIMS) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional inv
